Qu Biologics is a Vancouver-based private clinical stage biopharmaceutical company that develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer, inflammatory bowel disease (Crohn's disease, ulcerative colitis) and arthritis. 

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally. 

Over 250 cancer patients and 10 patients with inflammatory bowel disease (Crohn's and ulcerative colitis) have been treated to-date with SSIs through compassionate use programs, with no significant side effects reported. Animal studies have confirmed the inherent safety and efficacy of this approach.